DK3208269T3 - Inhibitorer af c-fms-kinase - Google Patents

Inhibitorer af c-fms-kinase Download PDF

Info

Publication number
DK3208269T3
DK3208269T3 DK16203884.8T DK16203884T DK3208269T3 DK 3208269 T3 DK3208269 T3 DK 3208269T3 DK 16203884 T DK16203884 T DK 16203884T DK 3208269 T3 DK3208269 T3 DK 3208269T3
Authority
DK
Denmark
Prior art keywords
chinase
fms
inhibitors
fms chinase
Prior art date
Application number
DK16203884.8T
Other languages
English (en)
Inventor
Carl R Illig
Jinsheng Chen
Sanath K Meegalla
Mark J Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK3208269T3 publication Critical patent/DK3208269T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
DK16203884.8T 2007-10-17 2008-10-16 Inhibitorer af c-fms-kinase DK3208269T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98062307P 2007-10-17 2007-10-17
EP08839490.3A EP2215079B1 (en) 2007-10-17 2008-10-16 Inhibitors of c-fms kinase

Publications (1)

Publication Number Publication Date
DK3208269T3 true DK3208269T3 (da) 2021-10-11

Family

ID=40352814

Family Applications (2)

Application Number Title Priority Date Filing Date
DK08839490.3T DK2215079T3 (da) 2007-10-17 2008-10-16 Inhibitorer af c-fms-kinase
DK16203884.8T DK3208269T3 (da) 2007-10-17 2008-10-16 Inhibitorer af c-fms-kinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK08839490.3T DK2215079T3 (da) 2007-10-17 2008-10-16 Inhibitorer af c-fms-kinase

Country Status (36)

Country Link
US (1) US8497376B2 (da)
EP (2) EP2215079B1 (da)
JP (1) JP5475672B2 (da)
KR (1) KR101559326B1 (da)
CN (1) CN101889009B (da)
AR (1) AR068892A1 (da)
AU (1) AU2008312540B2 (da)
BR (1) BRPI0817843B8 (da)
CA (1) CA2702898C (da)
CL (1) CL2008003068A1 (da)
CO (1) CO6270363A2 (da)
CR (1) CR11433A (da)
CY (2) CY1118717T1 (da)
DK (2) DK2215079T3 (da)
EA (1) EA018936B1 (da)
ES (2) ES2614754T3 (da)
HR (2) HRP20170393T1 (da)
HU (2) HUE056173T2 (da)
IL (1) IL205043A (da)
JO (1) JO3240B1 (da)
LT (2) LT2215079T (da)
MX (1) MX2010004263A (da)
MY (1) MY153951A (da)
NI (1) NI201000059A (da)
NZ (1) NZ584574A (da)
PA (1) PA8799701A1 (da)
PE (1) PE20090972A1 (da)
PL (2) PL3208269T3 (da)
PT (2) PT3208269T (da)
RS (2) RS62569B1 (da)
SI (2) SI3208269T1 (da)
TW (1) TWI440637B (da)
UA (1) UA99311C2 (da)
UY (1) UY31397A1 (da)
WO (1) WO2009052237A1 (da)
ZA (1) ZA201003429B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
MX2008013533A (es) * 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
CN107266405A (zh) 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
BR112015003393A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
MX365315B (es) * 2013-03-15 2019-05-29 Janssen Pharmaceutica Nv Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
AU2014235178A1 (en) * 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv 4-cyano-N-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)pyridin-3-yl)-1H-imidazole-2-carboxamide for the treatment of Hodgkin's lymphoma
CA2921298C (en) * 2013-08-16 2021-07-27 Janssen Pharmaceutica Nv Substituted imidazoles as n-type calcium channel blockers
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
EP3083576A4 (en) * 2013-12-19 2017-08-02 Archer Daniels Midland Co. Mono- and dialkyl ethers of furan-2,5-dimethanol and (tetra-hydrofuran-2,5-diyl)dimethanol and amphiphilic derivatives thereof
JP6537338B2 (ja) * 2015-04-24 2019-07-03 日東電工株式会社 核酸固相合成用リンカー及び担体
CA3013963A1 (en) * 2016-02-11 2017-08-17 Bayer Cropscience Aktiengesellschaft Substituted 2-oxyimidazolyl-carboxamides as pest control agents
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
TW201811326A (zh) 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020222109A1 (en) 2019-05-02 2020-11-05 Janssen Biotech, Inc. Csf-1/csf-1r gene set
CN110575450B (zh) * 2019-09-17 2023-03-31 遵义医科大学珠海校区 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用
CA3164126A1 (en) 2019-12-09 2021-06-17 Syndax Pharmaceuticals, Inc. Antibodies for the treatment of chronic graft versus host disease
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
EP4709719A1 (en) * 2023-06-09 2026-03-18 Modulo Bio, Inc. 5-cyano-1h-imidazole-2-carboxamide compounds as csf1r inhibitors

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1996011932A1 (en) 1994-10-14 1996-04-25 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
DE69623455T2 (de) 1995-04-19 2003-01-16 Schneider (Usa) Inc., Plymouth Beschichteter dilatator zur abgabe eines arzneistoffs
US6117432A (en) 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EE03484B1 (et) 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
JPH11514676A (ja) 1996-08-09 1999-12-14 メルク エンド カンパニー インコーポレーテッド 立体選択的脱酸素化反応
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
ATE252104T1 (de) 1996-12-20 2003-11-15 Tovarischestvo S Ogranichennoi Verfahren und gerät zur herstellung von 1ss, 10ss-epoxy-13-dimethylamino-guaia-3(4)-en-6,12- lid- hydrochlorid
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
BR9809398A (pt) 1997-04-25 2000-06-13 Janssen Pharmaceutica Nv Quinazolinonas que inibem a farnesil transferase
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
EP1060619B1 (en) 1998-03-05 2002-07-03 Formula One Administration Limited Data communication system
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
WO2000001691A1 (en) 1998-07-01 2000-01-13 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
CA2336848A1 (en) 1998-07-10 2000-01-20 Merck & Co., Inc. Novel angiogenesis inhibitors
ATE289602T1 (de) 1998-08-27 2005-03-15 Pfizer Prod Inc Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200101343T2 (tr) 1998-08-27 2001-09-21 Pfizer Products Inc. Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
BR9916827A (pt) 1998-12-23 2001-10-16 Janssen Pharmaceutica Nv Derivados de quinolina 1,2-anelados
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
IL145941A (en) 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
IL161156A0 (en) 2001-10-30 2004-08-31 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
AU2003258491A1 (en) 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
BR0315053A (pt) 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery CHINOLINE DERIVATIVES AND CHINAZOLINE DERIVATIVES AS INHIBITORS OF FLT3 AUTOPHOSPHORYLATION AND THE MEDICAL COMPOSITIONS CONTAINING THEREOF
CA2501932C (en) 2002-11-13 2014-03-11 Chiron Corporation Use of benzimidazole quinolinones for treating cancer
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
ATE425160T1 (de) 2002-12-18 2009-03-15 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
JP3819415B2 (ja) 2003-04-09 2006-09-06 日本たばこ産業株式会社 複素芳香５員環化合物及びその医薬用途
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20050113566A1 (en) 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
WO2004096795A2 (en) 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
MXPA06001094A (es) 2003-07-28 2006-04-11 Smithkline Beecham Corp Compuestos quimicos.
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
CA2554925A1 (en) 2004-01-30 2005-08-11 Ab Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
US7662837B2 (en) 2004-10-22 2010-02-16 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US7705042B2 (en) * 2004-10-22 2010-04-27 Janssen Pharmaceutica Nv Class of arylamide compounds useful as inhibitors of c-fms kinase
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
ES2611604T3 (es) * 2004-10-22 2017-05-09 Janssen Pharmaceutica Nv Inhibidores de la c fms quinasa
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
EP1951234A2 (en) * 2005-10-18 2008-08-06 Janssen Pharmaceutica N.V. Method of inhibiting flt3 kinase
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
MX2008013532A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Inhibidores de c-fms cinasa.
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.

Also Published As

Publication number Publication date
RS55860B1 (sr) 2017-08-31
PA8799701A1 (es) 2009-05-15
SI3208269T1 (sl) 2021-11-30
NI201000059A (es) 2010-09-13
MX2010004263A (es) 2010-05-03
PE20090972A1 (es) 2009-07-13
TWI440637B (zh) 2014-06-11
BRPI0817843A2 (pt) 2015-04-07
ES2905118T3 (es) 2022-04-07
CR11433A (es) 2011-01-14
DK2215079T3 (da) 2017-02-13
JP5475672B2 (ja) 2014-04-16
EA201070480A1 (ru) 2010-10-29
UY31397A1 (es) 2009-04-30
EP2215079A1 (en) 2010-08-11
ZA201003429B (en) 2011-08-31
PL2215079T3 (pl) 2017-06-30
PT3208269T (pt) 2021-12-09
AU2008312540B2 (en) 2014-03-27
HRP20170393T1 (hr) 2017-05-05
HUE056173T2 (hu) 2022-01-28
NZ584574A (en) 2011-12-22
BRPI0817843B8 (pt) 2021-05-25
LT3208269T (lt) 2021-11-10
PT2215079T (pt) 2017-03-23
CA2702898C (en) 2016-10-11
JO3240B1 (ar) 2018-03-08
IL205043A0 (en) 2010-11-30
CL2008003068A1 (es) 2009-03-06
MY153951A (en) 2015-04-15
SI2215079T1 (sl) 2017-05-31
AR068892A1 (es) 2009-12-16
EP3208269A1 (en) 2017-08-23
CY1124721T1 (el) 2022-07-22
EP3208269B1 (en) 2021-09-15
LT2215079T (lt) 2017-01-25
CA2702898A1 (en) 2009-04-23
US20090105296A1 (en) 2009-04-23
KR101559326B1 (ko) 2015-10-12
IL205043A (en) 2015-07-30
WO2009052237A1 (en) 2009-04-23
HRP20211593T1 (hr) 2022-03-18
AU2008312540A1 (en) 2009-04-23
CO6270363A2 (es) 2011-04-20
ES2614754T3 (es) 2017-06-01
KR20100069711A (ko) 2010-06-24
TW200932738A (en) 2009-08-01
EA018936B1 (ru) 2013-11-29
EP2215079B1 (en) 2016-12-14
RS62569B1 (sr) 2021-12-31
CY1118717T1 (el) 2017-07-12
CN101889009B (zh) 2014-10-29
PL3208269T3 (pl) 2022-01-10
US8497376B2 (en) 2013-07-30
CN101889009A (zh) 2010-11-17
UA99311C2 (en) 2012-08-10
BRPI0817843B1 (pt) 2019-01-02
JP2011501752A (ja) 2011-01-13
HUE031555T2 (en) 2017-07-28

Similar Documents

Publication Publication Date Title
CY2020023I2 (el) Αναστολεiς βητα-λακταμασων
DK2271642T3 (da) Pyridylinhibitorer af hedgehog signalering
DK2117523T3 (da) Inhibitorer af AKT-aktivitet
DK2421537T3 (da) Pyrazolylaminopyridiner som inhibitorer af FAK
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2015754T3 (da) Anvendelse af dpp-iv-inhibitorer
DK2091945T3 (da) Nye inhibitorer af glutaminylcyclase
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2262793T3 (da) Krystallinske former af nilotinib-hci
DK2086960T3 (da) Nye inhibitorer af glutaminylcyclase.
SMT201600267B (it) Inibitori di syk imidazopirazinici
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
DK2318396T5 (da) Krystalform af posaconazol
SMT201600291B (it) Inibitori di proteasi hcv
DK2848610T3 (da) Hæmmere af kinaseaktivitet
EP2299999A4 (en) STAT3 INHIBITORS
EP2192838A4 (en) HETEROCYCLIC NEKROPTOSIS HEMMER
EP2170073A4 (en) SELECTIVE INHIBITORS FOR CYCLINE-RELATED KINASES
DK2300461T3 (da) Cycliske inhibitorer af 11beta-hydroxysteroid-dehydrogenase 1
BRPI0817843A2 (pt) Inibidores da quinase c-fms
DK2219469T3 (da) Modificering af enzymatisk disponerede proteiner
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0918564A2 (pt) inibidores
BR112012005382A2 (pt) inibidores de jak
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer